It's a good question, not sure we have a good answer. Probably the elapsed time has not been long enough to form a good view on how Remestemcel-L is influencing ongoing sequelae.
Some people are going to gradually going to get better without it, others may be permanently injured, and maybe data will emerge that Remestemcel-L treated patients fare better in this regard...
Again in my view the best way forwards is a Phase 4 followup.
I am very concerned that lung fibrosis in particular will become refractory within weeks / a month and difficult to treat~
Overwhelming efficacy - the stats required, page-212
-
- There are more pages in this discussion • 365 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.065(6.07%) |
Mkt cap ! $1.147B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | $1.00 | $5.702M | 5.582M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 154906 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 130151 | 20 |
View Market Depth
| Last trade - 13.51pm 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |